Major General James G. Blunt

Piclozotan (SUN-N4057) is a selective 5-HT1A receptor partial agonist, which has neuroprotective effects in animal studies.[1] It has been through early clinical trials in humans for treatment of acute stroke, but results have not yet been announced.[2][3]

See also

References

  1. ^ Kamei K, Maeda N, Nomura K, Shibata M, Katsuragi-Ogino R, Koyama M, et al. (March 2006). "Synthesis, SAR studies, and evaluation of 1,4-benzoxazepine derivatives as selective 5-HT1A receptor agonists with neuroprotective effect: Discovery of Piclozotan". Bioorganic & Medicinal Chemistry. 14 (6): 1978–92. doi:10.1016/j.bmc.2005.10.046. PMID 16290165.
  2. ^ Ferro JM, Dávalos A (2006). "Other neuroprotective therapies on trial in acute stroke". Cerebrovascular Diseases. 21 Suppl 2 (2): 127–30. doi:10.1159/000091712. PMID 16651823. S2CID 39193793.
  3. ^ Mondick JT, Oo C, Patel D, Fujitani T, Shimizu K, Barrett JS (2009). "Population pharmacokinetics of the selective serotonin 5-HT1A receptor partial agonist piclozotan". American Journal of Therapeutics. 16 (2): 106–15. doi:10.1097/MJT.0b013e31816b8c85. PMID 19300037. S2CID 21284395.
source: https://en.wikipedia.org/wiki/Piclozotan